Replies to post #13099 on Mast Therapeutics, Inc. (MSTX)

[pray]

Doubt it; MSTX is the only company with no successful products in the past. Hopefully that will change soon. Real reason they are allowing Mr. Cully to present is to at least give Mast some face time. Looks like they feel sorry for him.

Check out the prices of the other contributors to the forum.
Global Blood Therapeutics (NASDAQ: GBT)
8 successful past tests; Present Stock Price $42.00

GlycoMimetics, Inc. (NASDAQ: GLYC)
3 successful past tests; Present Stock Price $9.00

Bluebird Bio (NASDAQ GS: BLUE)
14 successful past tests; Present Stock Price $130

Mast Therapeutics, Inc. (MSTX) formally ANX before reverse splite.
0 successful past tests; Present Stock Price .44 cents.

On the bright side this will give Mstx a chance to promote product line and hopefully get the price above $1.00 before the next offering.